Minerva Neurosciences, Inc. — FY2020 Form 10-K
Business context and reporting period. Annual report for the fiscal year ended December 31, 2020, filed March 8, 2021; it is not a standalone fourth-quarter filing. Minerva is a clinical-stage CNS biopharmaceutical company with no approved products or product-sales revenue. Its principal programs are roluperidone for schizophrenia’s negative symptoms and preclinical MIN-301 for Parkinson’s disease. The company opted out of its seltorexant collaboration with Janssen in 2020.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $41.2 million | None |
| Research and development expense | $22.0 million | $58.1 million |
| General and administrative expense | $17.3 million | $17.7 million |
| Operating income (loss) | $1.8 million | $(75.9) million |
| Net income (loss) | $1.9 million | $(72.2) million |
| Net cash used in operations | $(33.8) million | $(43.4) million |
- FY2020 revenue was entirely a one-time $41.2 million recognition of previously deferred Janssen collaboration amounts after Minerva opted out; it was not product revenue or a recurring revenue stream. The reported profit and operating margin therefore do not reflect established commercial operations.
- Cash, cash equivalents and restricted cash totaled $25.5 million at year-end, up $3.9 million year over year. Marketable securities were zero at year-end, versus $24.4 million in 2019.
- Minerva had total liabilities of $5.0 million, stockholders’ equity of $52.7 million and an accumulated deficit of $284.8 million. It reported no debt outstanding and no interest expense.
- FY2020 financing included approximately $12.1 million net proceeds from at-the-market stock sales and $1.1 million from option exercises; 3.38 million shares were sold under the ATM program.
- In January 2021, after year-end, Royalty Pharma paid $60 million upfront for Minerva’s seltorexant royalty interest, with up to $95 million in additional milestone payments contingent on development, regulatory and commercial events. Management said existing funds, including the upfront payment, were expected to cover commitments for at least 12 months after the financial statements were issued.
Material changes and operating developments
- R&D expense fell by $36.1 million, mainly reflecting the 2019 $19.0 million MIN-117 impairment, completion of its Phase 2b trial, and completion of roluperidone’s Phase 3 core study in May 2020. MIN-117 development for MDD was discontinued after the study missed endpoints.
- Roluperidone’s Phase 3 trial did not meet its primary or key secondary endpoints at Week 12 in the prespecified ITT analysis. The 64 mg dose had a nominal p-value of 0.044 on the primary endpoint in a modified ITT analysis excluding 17 patients from one site; FDA said whether to exclude those data requires review and the NDA would need to present results both with and without them.
- Deferred revenue of $41.2 million was eliminated following the Janssen opt-out. This largely explains the reduction in total liabilities from $49.7 million to $5.0 million.
- Cash from operations remained negative despite the reported net income; the cash-flow statement reflects the $41.2 million decrease in deferred revenue. The balance-sheet cash increase also benefited from marketable-security maturities and equity issuance.
Outlook, risks and contingencies
- Roluperidone regulatory uncertainty: FDA questioned the Phase 2b study’s non-U.S. conduct and different formulation, and said the Phase 3 ITT result did not establish substantial evidence of effectiveness. FDA cautioned that an NDA based on the existing studies would be highly unlikely to be filed and raised substantial concerns about lacking two adequate, well-controlled trials. Minerva disagreed that another efficacy trial was necessarily required and planned a formulation bioequivalence study, further FDA discussions and review of open-label extension data; extension results were expected in the first half of 2021.
- Development and funding: Management expects continuing losses and negative operating cash flow and says additional capital will be needed to fund later-stage development. Financing may dilute shareholders or be unavailable on acceptable terms. The company’s runway assertion includes the subsequent $60 million Royalty Pharma payment.
- Pipeline: MIN-301 remained in preclinical development, with an IND or IMPD filing and subsequent Phase 1 study contemplated; its regulatory pathway had not been determined. Seltorexant milestone proceeds depend on Janssen’s actions and milestones outside Minerva’s control. The royalty sale agreement may require Minerva to make makeup payments to Royalty Pharma if Janssen fails to pay royalties.
- Other risks: COVID-19 could disrupt operations or clinical development, although Minerva reported no material adverse operational impact to date. The company also relies on third parties for trials and manufacturing, faces regulatory, intellectual-property, reimbursement and competition risks, and had no product-liability insurance.
- Litigation: Two putative securities class actions alleged misleading statements concerning roluperidone and sought damages. Minerva disputed the claims; at filing, the cases were at a preliminary stage and the company could not estimate a reasonably possible loss or range of loss.
- The independent auditor issued an unqualified opinion on the financial statements and identified valuation of the $15.2 million in-process R&D asset as a critical audit matter. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an ICFR attestation.
Important facts for investors to verify
- Subsequent roluperidone bioequivalence and open-label extension results, and FDA’s response on whether the available efficacy evidence can support an NDA or further trials are required.
- Cash runway and future financing needs, distinguishing the $25.5 million year-end cash balance from the $60 million Royalty Pharma payment received under the January 2021 agreement.
- Conditions, timing and likelihood of Royalty Pharma’s up to $95 million in milestone payments, including any contractual makeup-payment exposure.
- Progress and funding requirements for MIN-301, and the eventual regulatory pathway for the candidate.
- Developments in the securities litigation and any resulting financial exposure, as well as the assumptions supporting the IPR&D asset’s carrying value.